A group of chemists and biologists are passionate about nucleic acid therapeutics, to be specific - morpholino oligonucleotides. Our team is dedicated to optimising the synthesis of Phosphorodiamidate Morpholino Oligonucleotides (PMOs). We are also concerned about nucleobase and backbone modification of the PMO backbone to optimize its efficacy as an antisense agent. The endeavour does not stop there!! The group is working towards intracellular delivery of PMOs, one of the major hurdles for any oligonucleotide therapeutics. Our approach includes the development of macromolecular delivery vehicles: peptidic (FAT) and non-peptidic delivery vehicles (IGT). Self-penetrating GMO-PMO chimera has also been developed for cancer treatment by downregulating the stemness genes responsible for recurrence and modulating the immunogenic pathways for immune evasion in cancer both in vitro and in vivo. Additionally, part of our team is also dedicated to replacing morphine by developing novel iboga analogues as pain alleviators.